skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

14 Total results for product and free and sample content found

Pink Sheet

US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

By Sue Sutter 22 Aug 2018

Accrual difficulties force changes that nullify Special Protocol Assessment; ongoing, randomized FOCUS trial in patients with ocular melanoma that has metastasized to liver will become single-arm study and target enrollment will be reduced by 66%.

Topic Clinical trials Drug approval Rare Disease FDA

Pink Sheet

Pharma Wants Clarity On Joint Evaluation Of EU Paediatric And Orphan Regulations

By Vibha Sharma 19 Jan 2018

The European Commission's plans to evaluate the EU pediatric and orphan drugs regulation in tandem.

Topic Rare Disease

Datamonitor Healthcare

Biosimilars in Inflammatory and Autoimmune Disease

12 Oct 2017

Biosimilars Development in Autoimmune and Inflammatory Diseases webinar

Topic Biosimilars Rare Disease


Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

By Lucie Ellis 04 Oct 2017

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy

Topic Rare Disease

Datamonitor Healthcare

Future of Regenerative Medicine

25 Sep 2017

Find out about the past, present and future of regenerative medicine. 

Topic Cancer Rare Disease

Pink Sheet

Orphan Biosimilar: Soliris Is One Target

14 Jun 2017

Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.

Topic Biosimilars Rare Disease Research

Pink Sheet

Disease Awareness Campaigns Still Must Tread Carefully, Observer Says

By Mark W. Sherman 04 Jun 2017

Sponsored plotline for General Hospital was careful to avoid irking US FDA; agency withdrew its guidance on disease awareness campaigns in 2015.

Topic Rare Disease

Pink Sheet

BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

By Emily Hayes 04 May 2017

Filing supporting Brineura was supported by a tiny, single-arm study and had no advisory committee review, the latest sign of the US regulatory agency's willingness to speed orphan drugs for serious pediatric diseases.

Topic Rare Disease


Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

By Lucie Ellis 23 Mar 2017

Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: